# US 2025/0002886 A1 · Engineered and chimeric nucleases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0002886 A1
- Document ID: US20250002886A1
- Status: Published application
- Kind: A1
- Application number: 18/885,463
- Filed: 2024-09-13
- Published: 2025-01-02
- Earliest claimed: 2022-03-14
- Assignees: Metagenomi, Inc.
- Applicants: Metagenomi, Inc.
- Inventors: Brian C. Thomas; Alan Brooks; Christopher Brown; Cristina Noel Butterfield; Daniela S.A. Goltsman; Jyun-Liang Lin; Isabel Nocedal; Morayma Temoche-Diaz
- Web page: https://patentgrep.com/patent/US20250002886A1

## CPC

- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/47: from mammals
- C07K 14/515: Angiogenesic factors; Angiogenin
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/723: {G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor}
- C07K 14/775: Apolipopeptides
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 9/14: Hydrolases (3)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/6454: {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/907: {in mammalian cells}
- C12Y 101/03015: (S)-2-Hydroxy-acid oxidase (1.1.3.15)
- C12Y 304/21061: Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
- C12Y 306/04006: Vesicle-fusing ATPase (3.6.4.6)
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein are engineered nucleases and nuclease systems, including chimeric nucleases and chimeric nuclease systems. Engineered and chimeric nucleases disclosed herein include nucleic acid guided nuclease. Additionally disclosed herein are methods of generating engineered nucleases and methods of using the same.

## Claims

### Claim 1

An engineered endonuclease, comprising:
a) an N-terminal portion comprising a sequence having at least 80% sequence identity to SEQ ID NO: 696; and
b) a C-terminal portion comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 697-721.

### Claim 2 (depends on 1)

The engineered endonuclease of claim 1, wherein the N-terminal portion and the C-terminal portion are fused directly to each other.

### Claim 3 (depends on 1)

The engineered endonuclease of claim 1, wherein the N-terminal portion and the C-terminal portion are joined by a linker.

### Claim 4 (depends on 3)

The engineered endonuclease of claim 3, wherein the linker is a glycine and/or serine-rich linker, a large protein domain, a long helix structure, or a short helix structure.

### Claim 5 (depends on 3, 4)

The engineered endonuclease of any one of claims 3-4, wherein the linker is (GGGGS)n, and wherein n is an integer from 1 to 20 SEQ ID NO: 2950).

### Claim 6 (depends on 3, 4)

The engineered endonuclease of any one of claims 3-4, wherein the linker is GGGGS (SEQ ID NO: 2864).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The engineered endonuclease of any one of claims 1-6, wherein the N-terminal portion comprises a sequence having at least 90% sequence identity to SEQ ID NO: 696.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The engineered endonuclease of any one of claims 1-6, wherein the N-terminal portion comprises a sequence having 100% sequence identity to SEQ ID NO: 696.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The engineered endonuclease of any one of claims 1-8, wherein the C-terminal portion comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 697-721.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The engineered endonuclease of any one of claims 1-8, wherein the C-terminal portion comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 697-721.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The engineered endonuclease of any one of claims 1-10, wherein the engineered endonuclease is configured to bind to a PAM that comprises any one of SEQ ID NOs: 60-66, 117, 865-919, and 2855-2863.

### Claim 12

An engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.

### Claim 13 (depends on 12)

The engineered endonuclease of claim 12, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.

### Claim 14 (depends on 12)

The engineered endonuclease of claim 12, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.

### Claim 15

An engineered endonuclease comprising a sequence having at least 80% sequence identity to SEQ ID NO: 10.

### Claim 16 (depends on 15)

The engineered endonuclease of claim 15, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to SEQ ID NO: 10.

### Claim 17 (depends on 15)

The engineered endonuclease of claim 15, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to SEQ ID NO: 10.

### Claim 18

An engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.

### Claim 19 (depends on 18)

The engineered endonuclease of claim 18, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.

### Claim 20 (depends on 18)

The engineered endonuclease of claim 18, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.

### Claim 21

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and to hybridize to a target nucleic acid sequence.

### Claim 22 (depends on 21)

The engineered nuclease system of claim 21, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.

### Claim 23 (depends on 21)

The engineered nuclease system of claim 21, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.

### Claim 24 (depends on 21, 22, 23)

The engineered nuclease system of any one of claims 21-23, wherein the engineered guide polynucleotide is a single guide nucleic acid.

### Claim 25 (depends on 21, 22, 23)

The engineered nuclease system of any one of claims 21-23, wherein the engineered guide polynucleotide is a dual guide nucleic acid.

### Claim 26 (depends on 21, 22, 23)

The engineered nuclease system of any one of claims 21-23, wherein the engineered guide polynucleotide is RNA.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The engineered nuclease system of any one of claims 21-26, wherein the engineered endonuclease binds non-covalently to the engineered guide polynucleotide.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26)

The engineered nuclease system of any one of claims 21-26, wherein the endonuclease is covalently linked to the engineered guide polynucleotide.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26)

The engineered nuclease system of any one of claims 21-26, wherein the endonuclease is fused to the engineered guide polynucleotide.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The engineered nuclease system of any one of claims 21-29, wherein the engineered guide polynucleotide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 28-45, 605-610, 646-695, 863, and 1789-1826.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The engineered nuclease system of any one of claims 21-29, wherein the engineered guide polynucleotide comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 28-45, 605-610, 646-695, 863, and 1789-1826.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The engineered nuclease system of any one of claims 21-31, wherein the engineered endonuclease is configured to bind to a PAM that comprises any one of SEQ ID NOs: 60-66, 865-919, and 2863.

### Claim 33

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and to hybridize to a target nucleic acid sequence.

### Claim 34 (depends on 33)

The engineered nuclease system of claim 33, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.

### Claim 35 (depends on 33)

The engineered nuclease system of claim 33, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.

### Claim 36 (depends on 33, 34, 35)

The engineered nuclease system of any one of claims 33-35, wherein the engineered guide polynucleotide is a single guide nucleic acid.

### Claim 37 (depends on 33, 34, 35)

The engineered nuclease system of any one of claims 33-35, wherein the engineered guide polynucleotide is a dual guide nucleic acid.

### Claim 38 (depends on 33, 34, 35)

The engineered nuclease system of any one of claims 33-35, wherein the engineered guide polynucleotide is RNA.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The engineered nuclease system of any one of claims 33-38, wherein the engineered endonuclease binds non-covalently to the engineered guide polynucleotide.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38)

The engineered nuclease system of any one of claims 33-38, wherein the endonuclease is covalently linked to the engineered guide polynucleotide.

### Claim 41 (depends on 33, 34, 35, 36, 37, 38)

The engineered nuclease system of any one of claims 33-38, wherein the endonuclease is fused to the engineered guide polynucleotide.

### Claim 42 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41)

The engineered nuclease system of any one of claims 33-41, wherein the engineered guide polynucleotide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 111-113.

### Claim 43 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41)

The engineered nuclease system of any one of claims 33-41, wherein the engineered guide polynucleotide comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 111-113.

### Claim 44 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The engineered nuclease system of any one of claims 33-43, wherein the engineered endonuclease is configured to bind to a PAM that comprises any one of SEQ ID NOs: 117 and 2855-2862.

### Claim 45

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 67-86.

### Claim 46

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.

### Claim 47 (depends on 46)

The engineered nuclease system of claim 46, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 139-158,925-927,992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.

### Claim 48

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 159-184.

### Claim 49 (depends on 48)

The engineered nuclease system of claim 48, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 185-210.

### Claim 50

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 211-251.

### Claim 51 (depends on 50)

The engineered nuclease system of claim 50, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 252-292.

### Claim 52

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC2 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 293-337.

### Claim 53 (depends on 52)

The engineered nuclease system of claim 52, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 338-382.

### Claim 54

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an ANGPTL3 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.

### Claim 55 (depends on 54)

The engineered nuclease system of claim 54, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389.

### Claim 56

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a PCSK9 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376.

### Claim 57 (depends on 56)

The engineered nuclease system of claim 56, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 588-602 and 1377-1391.

### Claim 58

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a VCP gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762.

### Claim 59 (depends on 58)

The engineered nuclease system of claim 58, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 739-754 and 763-770.

### Claim 60

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an AAVS1 locus or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049.

### Claim 61 (depends on 60)

The engineered nuclease system of claim 60, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 950-971 and 1050-1087.

### Claim 62

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a GPR146 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1588-1656.

### Claim 63 (depends on 62)

The engineered nuclease system of claim 62, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1657-1725.

### Claim 64

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an APOA1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961 and 2058-2088.

### Claim 65 (depends on 64)

The engineered nuclease system of claim 64, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.

### Claim 66

An engineered nuclease system, comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a HAO1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A method for modifying a target nucleic acid sequence comprising contacting the target nucleic acid sequence using the endonuclease of any one of claims 1-32 or the engineered nuclease system of any one of claims 33-66.

### Claim 68 (depends on 67)

The method of claim 67, wherein modifying the target nucleic acid sequence comprises binding, nicking, or cleaving, the target nucleic acid sequence.

### Claim 69 (depends on 67, 68)

The method of any one of claims 67-68, wherein the target nucleic acid sequence comprises genomic DNA, viral DNA, viral RNA, or bacterial DNA.

### Claim 70 (depends on 67, 68, 69)

The method of any one of claims 67-69, wherein the modification is in vitro.

### Claim 71 (depends on 67, 68, 69)

The method of any one of claims 67-69, wherein the modification is in vivo.

### Claim 72 (depends on 67, 68, 69)

The method of any one of claims 67-69, wherein the modification is ex vivo.

### Claim 73 (depends on 67, 68, 69, 70, 71, 72)

The method of any one of claims 67-72, wherein the gRNA is encoded by a sequence having any one of SEQ ID NOs: 251-260, 271-274, and 279-290.

### Claim 74 (depends on 67, 68, 69, 70, 71, 72)

The method of any one of claims 67-72, wherein the target nucleic acid sequence comprises a sequence having any one of SEQ ID NOs: 261-270, 275-278, and 291-302.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A method of modifying a target nucleic acid sequence in a mammalian cell comprising contacting the mammalian cell using the endonuclease of any one of claims 1-32 or the engineered nuclease system of any one of claims 33-66.

### Claim 76 (depends on 75)

The method of claim 75, further comprising selecting cells comprising the modification.

### Claim 77

A method of modifying an albumin gene comprising contacting the albumin gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 67-86.

### Claim 78

A method of modifying a TRAC gene comprising contacting the TRAC gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.

### Claim 79 (depends on 78)

The method of claim 78, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.

### Claim 80

A method of modifying a B2M gene comprising contacting the B2M gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 159-184.

### Claim 81 (depends on 80)

The method of claim 80, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 185-210.

### Claim 82

A method of modifying a TRBC1 gene comprising contacting the TRBC1 gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 211-251.

### Claim 83 (depends on 82)

The method of claim 82, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 252-292.

### Claim 84

A method of modifying a TRBC2 gene comprising contacting the TRBC2 gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the TRBC2 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 293-337.

### Claim 85 (depends on 84)

The method of claim 84, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 338-382.

### Claim 86

A method of modifying an ANGPTL3 gene comprising contacting the ANGPTL3 gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the ANGPTL3 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.

### Claim 87 (depends on 86)

The method of claim 86, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389.

### Claim 88

A method of modifying a PCSK9 gene comprising contacting the PCSK9 gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the PCSK9 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376.

### Claim 89 (depends on 88)

The method of claim 88, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 588-602 and 1377-1391.

### Claim 90

A method of modifying a VCP gene comprising contacting the VCP gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the VCP gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762.

### Claim 91 (depends on 90)

The method of claim 90, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 739-754 and 763-770.

### Claim 92

A method of modifying an AAVS1 locus comprising contacting the AAVS1 locus using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the AAVS1 locus or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049.

### Claim 93 (depends on 92)

The method of claim 92, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 950-971 and 1050-1087.

### Claim 94

A method of modifying a GPR146 gene comprising contacting the GPR146 gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the GPR146 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1588-1656.

### Claim 95 (depends on 94)

The method of claim 94, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1657-1725.

### Claim 96

A method of modifying an APOA1 gene comprising contacting the APOA1 gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the APOA1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961 and 2058-2088.

### Claim 97 (depends on 96)

The method of claim 96, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.

### Claim 98

A method of modifying a TRAC gene comprising contacting the TRAC gene using an engineered nuclease system comprising:
a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and
b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a HAO1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A cell comprising the endonuclease of any one of claims 1-32 or the engineered nuclease system of any one of claims 33-66.

### Claim 100 (depends on 99)

The cell of claim 99, wherein the cell is a eukaryotic cell.

### Claim 101 (depends on 99)

The cell of claim 99, wherein the cell is a mammalian cell.

### Claim 102 (depends on 99)

The cell of claim 99, wherein the cell is an immortalized cell.

### Claim 103 (depends on 99)

The cell of claim 99, wherein the cell is an insect cell.

### Claim 104 (depends on 99)

The cell of claim 99, wherein the cell is a yeast cell.

### Claim 105 (depends on 99)

The cell of claim 99, wherein the cell is a plant cell.

### Claim 106 (depends on 99)

The cell of claim 99, wherein the cell is a fungal cell.

### Claim 107 (depends on 99)

The cell of claim 99, wherein the cell is a prokaryotic cell.

### Claim 108 (depends on 99)

The cell of claim 99, wherein the cell is an A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, primary cell, or a derivative thereof.

### Claim 109 (depends on 99)

The cell of claim 99, wherein the cell is an engineered cell.

### Claim 110 (depends on 99)

The cell of claim 99, wherein the cell is a stable cell.
